Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Fineline Cube Feb 9, 2026
Company Drug

Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma

Fineline Cube Feb 9, 2026
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025

The National Healthcare Security Administration (NHSA) released the 2025 National Medical Insurance Drug List and...

Company Deals

OTR Therapeutics Series-A Raises $100M for Neurology Pipeline

Fineline Cube Dec 8, 2025

OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing,...

Company Deals

Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform

Fineline Cube Dec 5, 2025

Sanofi (NASDAQ: SNY) announced the completion of its $1.6 billion acquisition of Vicebio, first announced in...

Company Drug

Juventas CAR-T LBCL Launch Marks Second Indication

Fineline Cube Dec 5, 2025

Juventas Cell Therapy Ltd announced the commercial launch of inaticabtagene autoleucel for relapsed or refractory...

Company Drug

BMS Breyanzi MZL FDA Approval First CAR-T

Fineline Cube Dec 5, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the FDA has approved Breyanzi (lisocabtagene maraleucel; liso-cel)...

Company Deals

Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient

Fineline Cube Dec 5, 2025

Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd.,...

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Fineline Cube Dec 4, 2025

Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer’s Disease conference that semaglutide...

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Fineline Cube Dec 4, 2025

Acotec Scientific Holdings Limited (HKG: 6669) announced it has received registration approval from China’s National...

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Fineline Cube Dec 4, 2025

Youjia Biomedical Technology and Hangzhou Tongee Medical Technology Co., Ltd officially signed a strategic cooperation...

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod

Fineline Cube Dec 4, 2025

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its FXS0887 tablet has...

Company Drug

TransThera Tinengotinib Cholangiocarcinoma Priority Review China

Fineline Cube Dec 4, 2025

TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the...

Company Deals R&D

Bio-Sincerity UCAS R&D Center Pharma Synthesis

Fineline Cube Dec 4, 2025

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) announced the signing of a cooperation agreement with...

Company Drug

Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss

Fineline Cube Dec 4, 2025

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...

Company Drug

Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma

Fineline Cube Dec 4, 2025

Beijing Gene Mink Biotechnology announced that its self-developed QM103 Cell Injection, a BCMA‑targeted CAR‑NK cell...

Company Drug

CSPC SYH2056 FDA Approval Targets Depression with 5-HT2A Agonist

Fineline Cube Dec 4, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056 tablets, a Category 1 chemical drug, has...

Company Drug

Antengene XPOVIO sNDA Hong-Kong Approval Expands MM DLBCL Indications

Fineline Cube Dec 4, 2025

Antengene Corporation Limited (HKG: 6996) announced that Hong Kong’s Department of Health approved two supplementary...

Company Drug

Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership

Fineline Cube Dec 4, 2025

Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324,...

Policy / Regulatory

NHSA Guangzhou Drug-List Conference Releases 2025 Medical Insurance Formulary

Fineline Cube Dec 4, 2025

The National Healthcare Security Administration (NHSA) announced it will host the 2025 Innovative Drugs High-Quality...

Company Deals

Simcere deuremidevir RSV Licensing Deal Targets China Breakthrough

Fineline Cube Dec 4, 2025

Simcere Pharmaceutical Group Limited (HKG: 2096) and Vigonvita Life Sciences Co., Ltd. (HKG: 2630) entered...

Company Deals

Henlius Fovinaciclib CDK4-6 Breast-Cancer China Commercialization

Fineline Cube Dec 4, 2025

Henlius Biotech (HKG: 2696) announced a collaboration with Avanc Pharmaceutical Co., Ltd. to advance the...

Posts pagination

1 … 27 28 29 … 621

Recent updates

  • Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market
  • Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego
  • Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer
  • Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma
  • Jenscare Scientific’s LuX-Valve Plus Wins FDA Nod for US Pivotal Trial in Tricuspid Regurgitation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market

Company

Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego

Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Company Drug

Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.